Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trials
出版年份 2022 全文链接
标题
Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trials
作者
关键词
-
出版物
STATISTICAL METHODS IN MEDICAL RESEARCH
Volume -, Issue -, Pages 096228022211026
出版商
SAGE Publications
发表日期
2022-06-01
DOI
10.1177/09622802221102621
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Are restricted mean survival time methods especially useful for noninferiority trials?
- (2021) Boris Freidlin et al. Clinical Trials
- Evaluation of the Change of Outcomes over a Ten-Year Period in Patients with Stage III Colon Cancer: Pooled Analysis of 6501 Patients Treated with Fluorouracil, Leucovorin, and Oxaliplatin in the ACCENT Database
- (2020) M.E. Salem et al. ANNALS OF ONCOLOGY
- On the empirical choice of the time window for restricted mean survival time
- (2020) Lu Tian et al. BIOMETRICS
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
- (2020) Thierry André et al. LANCET ONCOLOGY
- Multivariate meta-analysis model for the difference in restricted mean survival times
- (2019) Isabelle R Weir et al. BIOSTATISTICS
- Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development
- (2019) David H. Manner et al. AMERICAN HEART JOURNAL
- Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials
- (2018) Xianmixikemaier Abulizi et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design of non-inferiority randomized trials using the difference in restricted mean survival times
- (2018) Isabelle R Weir et al. Clinical Trials
- Adaptive non-inferiority margins under observable non-constancy
- (2018) Brett Hanscom et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer
- (2017) Naruhiko Ikoma et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies
- (2015) Hajime Uno et al. ANNALS OF INTERNAL MEDICINE
- On the restricted mean survival time curve in survival analysis
- (2015) Lihui Zhao et al. BIOMETRICS
- Meta-analysis in clinical trials revisited
- (2015) Rebecca DerSimonian et al. Contemporary Clinical Trials
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study
- (2015) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
- (2014) Hajime Uno et al. JOURNAL OF CLINICAL ONCOLOGY
- Predicting the restricted mean event time with the subject's baseline covariates in survival analysis
- (2013) L. Tian et al. BIOSTATISTICS
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
- (2013) Patrick Royston et al. BMC Medical Research Methodology
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started